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on-metal (MOM) hip implants continues. With over 1 
million patients affected worldwide, the impact is far 
reaching. The majority of the aggressive failures of 
MOM hip implants have been dealt with by revision hip 
surgery, leaving patients with a much more indolent 
pattern of failure of devices that have been in situ  for 
more than 10 years. The longer-term outcome for such 
patients remains unknown, and much debate exists on 
how best to manage these patients. Regulatory guidance 
is available but remains open to interpretation due to 
the lack of current evidence and long-term studies. 
Metal ion thresholds for concern have been suggested 
at 7 ppb for hip resurfacing arthroplasty and below this 
level for large diameter total hip arthroplasties. Soft 
tissue changes including pseudotumours and muscle 
atrophy have been shown to progress, but this is not 
consistent. New advanced imaging techniques are 
helping to diagnose complications with metal hips and 
the reasons for failure, however these are not widely 
available. This has led to some centres to tackle difficult 
cases through multidisciplinary collaboration, for both 
surgical management decisions and also follow-up 
decisions. We summarise current evidence and consider 
who is at risk, when revision should be undertaken and 
how patients should be managed. 
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Core tip: Evidence supporting the management of 
metal on metal hips is lacking, and guidance is open to 
interpretation. Until supporting evidence is available, 
an evidence based multi-disciplinary approach on a 
case-by-case basis is considered a safe method to 
help surgeons make decisions and potentially improve 
patient outcomes.
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Abstract
The debate on how best to manage patients with metal-
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INTRODUCTION
Considerable debate continues to surround the use 
and management of patients with failing metal-on-
metal (MOM) hip implants. Over a million patients 
worldwide have been implanted with a MOM device[1], 
and according to the United Kingdom National Joint 
Registry (NJR), their use peaked in 2006 [hip resurfacing 
arthroplasty (HRA)] and 2008 [large diameter total 
hip replacement (LDTHR)][2]. However, due to several 
concerns of catastrophic soft tissue reactions leading 
to early failures and associated complications, medical 
device alerts were published[3], and MOM hips were 
subsequently withdrawn from use by the British Hip 
Society in 2012. 
It is clear that there are evolving and changing 
patterns of behaviour in the failure of MOM hips[4]. Many 
of the early, aggressive failures have been dealt with 
by revision hip surgery, and we now see a much more 
indolent pattern of failure in patients who have had 
devices in situ for more than 10 years. 
This spectrum of patients from the well functioning, 
that require only monitoring, to the poorly functioning, 
which require revision continues to evoke debate 
among surgeons, especially since the bulk of patients 
fall between these two extremes Figures 1 and 2. 
Uncertainties surround thresholds for investigation, revi-
sion surgery and methods for surveillance[5]. Guidance 
from international regulatory agencies exists, but 
tend to reflect the needs of local health authorities, 
which accounts for some of the variation seen in the 
guidance[3,6,7]. 
This review examines the literature on current 
clinical dilemmas facing surgeons and their patients 
with MOM hip replacements, and summarises current 
clinical guidance for how and when patients should be 
managed.
MOM hip implants
MOM hip implants consist of two broad types, the HRA 
and the LDTHR. Since their inception in 1937[4], they 
have gone through several key design changes and 
modifications, with the expected fluctuations in their use. 
Their use flourished in the 1990s with the introduction 
of the modern HRA and subsequently accounted for 
approximately a third of all hip replacements being 
implanted in the United States in 2008[1].
The proposed benefits for using MOM bearings were 
to reduce the occurrence of polyethylene disease (ase-
ptic loosening) and to allow the use of large diameter 
femoral head components to reduce the occurrence of 
hip dislocation[4]. However, the inception of highly cross-
linked polyethylene and improved ceramic bearing 
design, have diminished the perceived advantages of 
MOM over other bearing surfaces[8,9]. 
Besides this, metal debris and corrosion products 
have led to inflammatory reactions within the soft 
tissues surrounding MOM hip implants and subsequently 
their early failure and need for revision[10-13]. This has 
led to the subsequent fall in use of MOM hips and 
intervention from regulators[3]. 
Metal debris - A cause for concern?
Metal implants are considered biologically inert, however 
wear debris is not and is thought to evoke an immune 
response[14]. The release of material from metallic 
implants occurs by wear, corrosion and mechanical 
factors such as fretting and third body wear. Cobalt and 
chromium are the major constituents of alloy metal 
implants, and are the main cause for concern. 
Metal particulate and ionic wear debris from the hip 
is released into the peri-prosthetic tissues and trans-
ported systemically throughout the body[15,16]. Studies 
have demonstrated a peak in blood cobalt levels at 
6-mo post implantation and chromium levels at 9-mo, 
followed by a steady decline over time[17,18]. Following 
revision of a MOM implant to an alternative bearing, 
blood ion levels reduce but do not normalise in the post-
operative period[19,20]. 
Component design and positioning has been shown 
to be associated with increased wear and as a result 
raised metal ion levels[21-25]. Blood cobalt and chromium 
ion levels in patients with unexplained painful MOM hips 
are double those of well-functioning MOM hips[13]. 
Wear debris can accumulate locally as seen by studies 
of joint fluid surrounding MOM hip implants[26-28]. The 
level of chromium is greater in joint fluid compared to 
cobalt, whereas the converse is true for blood analysis[28]. 
However it is believed that cobalt is the species with 
greatest reactivity causing local tissue inflammatory 
reactions due to its ready solubility[29-31]. 
WHO IS AT RISK?
Local soft tissue reactions
Pseudotumours are well described in patients with MOM 
hip implants, and can be either solid or cystic. Reported 
prevalence in both symptomatic and asymptomatic 
patients ranges from 0.1% to 69%[10,11,32-37]. The precise 
aetiology is not known, however the term aseptic lym-
phocytic vasculitis-associated lesion (ALVAL) is used 
to describe the histological features associated with 
metal hips[38]. It has been suggested that a delayed 
type Ⅳ hypersensitivity reaction to metal ions is the 
potential cause, however this has been challenged[12]. 
Pseudotumours were, however, shown to correlate 
with elevated blood and hip aspirate metal ion levels 
suggesting a relation to excessive implant wear[12,39].
Recent evidence regarding the natural history of 
soft tissues abnormalities is conflicting. Studies report 
varying degrees of progression in size and grade of 
pseudotumours, however limitations in sample size, 
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implant type and imaging modality do not readily allow 
the generalisability of the results[40-42]. It appears that 
when disease progression does occur, it is slow and 
therefore serial imaging annually is sufficient to identify 
change. The potential to cause local pressure effects 
causing necrosis and compression of nearby structures 
such as the iliac vessels, femoral vessels and the sciatic 
nerve is also a concern.
Muscle atrophy is now becoming an increasing 
concern, and is driving the debate regarding the timing 
of revision surgery in order to prevent irreversible 
damage. A recent publication demonstrated progressive 
muscle atrophy using serial magnetic resonance imaging 
(MRI) scanning in a mixed cohort of patients[43].
Systemic effects
Several cases of systemic effects from metal hip implants 
have been reported, including cardiac, endocrine, 
neurological and dermatological complications, however 
this remains a relatively rare occurrence[44]. There is a 
mixture of cases reported in both fractured ceramic hips 
and in primary MOM hip patients[44]. Removal of the 
implant led to reduced metal ion levels and symptomatic 
improvement in several of these cases. Additionally, 
chronic low dose exposure over several years revealed a 
negative effect on cardiac function and bone density[45], 
however these were subtle and sub-clinical. Recent 
cases of cardiac toxicity have been further highlighted 
and novel diagnostic techniques are being explored[46,47].
MANAGEMENT - WHEN SHOULD 
PATIENTS BE REVISED?
The local and systemic effects of metal particulate and 
ionic debris from MOM hips have led to increased rates 
of revision hip surgery. It has also led to significant 
levels of patient anxiety, not to mention the physical 
and financial burden of a failed metal implant on the 
patient and the health services. 
The British Hip Society was the first to publish their 
guidance through the Medicines and Healthcare Products 
Regulatory Agency (MHRA)[3]. The MOM task force 
(American Association of Hip and Knee Surgeons, the 
American Academy of Orthopaedic Surgeons, and The 
Hip Society) in the United States[48], the European Hip 
Society (EHS) (2012)[6], and most recently the European 
Commission’s Scientific Committee on Emerging and 
Newly Identified Health Risks, have also published 
guidance for surgeons[49]. However, uncertainties remain 
over decision making because of the difficulty - for any 
guideline - to define or quantify clinical symptoms, 
imaging findings and clinically important thresholds for 
blood metal ion results.
Role of metal ions
The MHRA currently recommends 7 ppb as the thres-
hold for concern beyond which further investigations 
are recommended to diagnose complications associated
with MOM hip implants. The Food and Drug Admini-
stration (FDA) does not currently set an action level, and 
SCENIHR acknowledge that the level for concern lies 
between 2-7 ppb based on questions raised regarding 
the current available evidence.
The population background level of cobalt in blood 
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No pain/minor abnormality 
on baseline data fields, 
e.g. , Synovitis
Monitor, but 
guidance is not clear
Monitor, but 
guidance lacking
Systemic symptoms Moderate abnormalities
   Blood metal ions 5-10 ppb
   MARS MRI 
      Cystic pseudotumour
      Muscle atrophy
   Moderate symptoms 
Uncertain management
Severe pain with large 
cystic/solid pseudotumour 
or muscle damage
Revision surgery
Spectrum of concern
Figure 1  Diagram demonstrating the spectrum of concern for patients with metal-on-meta hip implants. The decision on how to manage patients at the 
extremes of the spectrum is relatively straightforward. However the majority of patients fall into to the middle category, where the management is uncertain or difficult. 
MRI: Magnetic resonance imaging; MARS: Metal artefact reduction sequence.
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Figure 2  Middle of the spectrum - A typical patient with moderate problems. 
This 58-year-old very active lady with a right hip resurfacing arthroplasty (A: X-ray 
AP hip) implanted 8 years ago. She has minimal symptoms and moderately 
raised blood metal ion levels (Cobalt 13 ppb, Chromium 7 ppb). A magnetic 
resonance imaging scan (B: Axial T2 weighted image) has revealed a 6 cm cystic 
pseudotumour anterior to the hip (arrows). 
A B
threshold for concern.
Role of diagnostic imaging
The MHRA advise metal artefact reduction sequence 
MRI (MARS MRI) or ultrasound scan as part of the 
investigation algorithm[3]. MARS MRI appears more 
appropriate, due to excellent sensitivity and specificity 
for detection of both superficial and deep lesions[53-55], 
and also muscle atrophy. Ultrasound is a satisfactory 
modality for identifying tendon abnormalities[54]. Current 
MARS MRI techniques do suffer from metal artefact that 
limits the diagnosis of osteolysis, however, improved 
techniques are being developed[56]. Currently computed 
tomography (CT) scanning is ideal for visualising oste-
olysis if it is suspected on plain radiographs[57].
In patients where the cause of pain is unexplained, 
single-photon emission CT (SPECT-CT) has been re-
commended[58]. SPECT-CT was shown to be clinically 
valuable in diagnosing the cause of pain and influenced 
management decisions in over half of patients with 
unexplained pain following a MOM hip arthroplasty 
despite inconclusive conventional investigations.
Pseudotumours
There is a lack of evidence surrounding the need for 
revision secondary to pseudotumours, particularly 
regarding the outcome following revision surgery and 
the long-term natural history of pseudotumours. This is 
reflected in the current guidance by the limited detail in 
how to interpret MRI findings. 
It has been shown that revision for pseudotumour 
is associated with significant post-operative compli-
cations[59]. In addition, recurrence after revision with 
excision is possible and may be as high as 30%. If 
pseudotumours, cystic or solid, are large enough to 
cause pressure necrosis or stretch of soft tissues, then 
this is usually an indication for revision surgery (Figure 3). 
Large pseudotumours with intra-pelvic extensions 
along the psoas sheath or arising wholly within the pelvis 
are of particular concern. These have the potential for 
compression of neurovascular structures including the 
iliac vessels. In addition, surgical excision becomes more 
difficult and often a multi-disciplinary surgical approach 
with vascular surgeons is required (Figure 4).
Osteolysis
Osteolysis surrounding MOM hip implants is a further 
concern that needs to be addressed[60], and one should 
be vigilant in the presence of very high metal ions. 
Progressive osteolysis may be an indication for early 
intervention if the potential for peri-prosthetic fracture is 
apparent. 
Muscle atrophy
There is growing evidence supporting early revision 
to a non-MOM hip implant to prevent irreversible da-
mage[38,61]. Campbell et al[62] observed that patients 
can expect a good outcome if their soft tissues remain 
has been shown to be 0.5 ppb. There is a correlation 
seen with wear rates, where 2 ppb can be expected 
with wear rates of 2 cubic mm per year[50,51]. 
Since the 7 ppb level was derived from research 
based on hip resurfacings[51], it has been postulated 
that this may not apply to stemmed implants. A study 
including a variety of implant types demonstrated 
improved sensitivity and specificity with a threshold 
cobalt level of 4.5 ppb[50]. 
Various groups have argued for a blood metal ion 
threshold for revision. The prevalence of patients with 
blood metal ion levels over 25 ppb was 2.6% in HRA 
patients, and 3.1% in total Hip Replacement (THR) 
patients[52]. The sensitivity and specificity of the 7 ppb 
cut-off level have been reported to be 52% and 89%, 
respectively, indicating that the 7 ppb has relative poor 
ability to identify MOM failures. The lowering of the 
cut-off level to 5 ppb increases the sensitivity to 63% 
and lowers specificity to 86%[51]. The Finland group 
demonstrated that 25 ppb was 99% specific compared 
to 93% specificity at 7 ppb, however more notably 
revised patients with metal ions over 25 ppb had a 
significantly lower oxford hip score 12 mo after revision 
compared to those with ions less than 25 ppb. The re-
revision rate was also higher in those patients with 
metal ions over 25 ppb[52].
Based on current literature 7 ppb remains a safe level 
for concern in patients with a HRA implant, whereas 
the presence of a taper (LDTHR) would prompt a lower 
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Figure 3  Axial (A) and coronal (B) magnetic resonance imaging. Example 
of abductor stripping secondary to a pseudotumour (marked by arrows). The 
pseudotumour can be seen traversing the posterior hip around the greater 
tuberosity onto its lateral aspect, which is now void of abductor tendon insertion.
A
B
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intact. A recent study demonstrated progressive muscle 
atrophy over a period of 12 mo using serial MRI, and 
noted an association with high metal ion levels[43]. Liddle 
et al[63] highlight the degree of misdiagnosis possible 
when planning for revision of MOM hip implants. They 
describe that pre-operative imaging can underestimate 
the degree of soft tissue abnormalities seen at revision 
surgery including a high rate of severe abductor muscle 
atrophy and stripping of the tendinous attachment[63]. 
If progressive and destructive soft tissue change is 
possible, predicting those patients that are likely to fail is 
paramount so that revision can be undertaken early to 
ensure a better outcome (Figure 3).
Broadly however, a decision to revise should not be 
based on a single investigation, instead the decision 
should take into account patient symptoms, activity level, 
implant type, metal ion levels and imaging findings.
WHEN SHOULD PATIENTS BE 
FOLLOWED UP?
Current guidance stratifies patients by risk depending 
on the type of implant they have in situ. Small dia-
meter THR and hip resurfacing arthroplasty is consi-
dered low risk, where as the large diameter THR 
and the DePuy ASR implants are considered high 
risk[3]. A recent publication went one step further and 
stratified all current generation MOM hip implants into 
low, medium and high risk categories[5], based on 
registry and regulatory advice. More recently however 
the Regulators state that low risk implants that are 
functioning well should be monitored according to local 
hospital protocols, whereas high-risk implants require 
follow-up for the life of the implant. The Birmingham 
Hip Resurfacing (Smith and Nephew, London, United 
Kingdom) has been the best performing hip resurfacing, 
however concerns have always existed regarding their 
use in female patients, and patients with small diameter 
femoral heads (< 48 mm). As a result of these concerns 
the MHRA have released further guidance advising 
against their use in this population and additional advice 
on the management of patients with these implants in 
situ[64]. 
However the majority of guidelines do not offer detail 
on what constitutes follow up, and more importantly 
which patients require more frequent monitoring. A 
pragmatic approach would be to take this on a case-by-
case basis where the frequency of follow up needs to 
be tailored to the individual based on the implant risk 
stratification and the patients clinical status. 
Based on the literature, with particular reference 
to the natural history of soft tissue changes, annual 
follow up would suffice for those with a medium to 
high risk implant. Follow up should consist of a history, 
clinical examination, functional scoring, blood metal 
ions measurement and X-ray. If clinical concern exists 
then cross sectional imaging with MARS MRI would be 
indicated. For low risk implants in individuals with a 
low risk profile, then less intensive follow-up would be 
indicated, such as annual questionnaires and 5-yearly 
clinical review. 
One must be mindful of applying a simplistic appro-
ach based on implant risk stratification alone, since 
certain aspects of the patients clinical and surgical 
history would suggest a heightened risk even in the best 
performing hip implants. Low risk implants in patients 
with hip symptoms, evidence of soft tissue abnormality 
or high metal ions would require closer monitoring. In 
addition, excessive acetabular cup inclination can lead 
to edge loading and early failure[65,66], and also female 
patients with small femoral head size hip resurfacing 
arthroplasties and females with primary hip dysplasia 
have worse long term outcomes[48].
HOW - MULTI-DISCIPLINARY TEAM 
APPROACH
Some clinical cases are straightforward and decision-
making is relatively easy. However, in many instances 
surgeons experience considerable uncertainty in deci-
sion-making because of the lack of guidelines or the 
difficulty in applying guidelines in complex cases. This 
gap has led to the use of a multidisciplinary teams (MDT) 
approach to help interpret the guidance published by 
the regulatory agencies, with the aim of using surgical 
experience, tacit knowledge, and evidence-based current 
best practice to reduce the uncertainty surrounding the 
management of patients with MOM hip implants[5].
This highlights the need for a more collaborative 
approach between surgeons, regulators and industry 
representatives to improve the available evidence and 
the guidance offered to aid the management of patients 
with MOM hip implants.
Role of retrievals
In a recent commentary by Jacobs et al[67], the im-
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Figure 4  A 58-year-old patient with bilateral large diameter total hip re-
placement metal-on-meta implanted 9-years ago, moderate hip symptoms 
and raised metal ion levels (Cobalt 17 ppb, Chromium 13 ppb). She presented 
to the general surgeons with abdominal pain and distension. Coronal magnetic 
resonance imaging scan (above) demonstrated a large cystic pseudotumour 
extending into the pelvis up to the level of the L2 vertebra and abutting the right 
kidney in the retroperitoneal space (arrows). The cystic pseudotumour was 
drained prior to surgical excision with both orthopaedic and vascular surgeons 
present.
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portance of implant retrieval analysis by centres with 
access to large retrieval cohorts was emphasized as 
significant in understanding mechanisms of failure and 
also for developing future preclinical testing models. 
This reflects the number of developments established 
through retrieval analysis and includes the relationship 
with cup position and edge loading[68], the correlation of 
wear rates with blood metal ion levels[66] and the role of 
frictional torque and fretting currents in LDTHR[69].
CONCLUSION
The management of patients with MOM hip implants 
continues to cause concern and difficulties for patients 
and surgeons alike. The evidence is lacking in certain 
scenarios, and regulatory guidance can be interpreted 
differently. When considering which patient requires 
revision, no single investigation or aspect of the history 
should be taken in isolation. Decisions should be taken 
on a case-by-case basis, with consideration given to 
all aspects of the patient’s clinical history and inves-
tigation results. A multi-disciplinary approach with 
shared decision-making, tacit knowledge and surgical 
experience appears to be a safe and practical approach 
to improving patient’s outcomes.
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